Orphan designation: post-authorisation

  • Email
  • Help

The pages listed below are relevant for sponsors of medicines that have obtained orphan designation and are at the post-authorisation (PA) stage of the product lifecycle.

In this section

In other sections

Sponsors of designated orphan medicines at the post-authorisation stage should also consider the regulatory information in the sections below:

How helpful is this page?

Average rating:

 Based on 2 ratings

Add your rating:

See all ratings
1 ratings
1 ratings
0 ratings
0 ratings
0 ratings

Tell us more

Related content